Skip to main content
. 2022 Mar 16;13(5):779–785. doi: 10.1021/acsmedchemlett.1c00702

Table 1. Calculated Rate Constants (kn), Inhibition Constants (Kn), and Dissociation Half-Lives (t1/2) for Compounds 3, 4, and 5a.

  HDAC1 HDAC2 HDAC3c
Entinostat (3)
k2 (min–1) 0.5 ± 0.1 0.28 ± 0.04 0.6 ± 0.5
k–2 (min–1) ∼7 × 10–9 ∼3 × 10–3 ∼7 × 10–3
Ki,1 (nM) 590 ± 400 590 ± 340 ∼3200
Ki (nM) b ∼6 ∼39
t1/2 (min) >105 ≥240 ≥95
RGFP966 (4)
k2 (min–1) 0.4 ± 0.1 0.38 ± 0.03 0.3 ± 0.1
k–2 (min–1) ∼2 × 10–2 ∼7 × 10–3 ∼5 × 10–3
Ki,1 (nM) 1300 ± 1000 1700 ± 400 700 ± 700
Ki (nM) ∼57 ∼31 ∼13
t1/2 (min) ≥36 ≥95 ≥131
Compound 5
k1 (nM–1·min–1) (7.8 ± 0.4) × 10–5 (5.1 ± 0.2) × 10–5  
k–1 (min–1) (3 ± 3) × 10–3 (5 ± 2) × 10–3  
Ki (nM) ∼40 ∼103  
t1/2 (min) ∼220 ∼130  
k2 (min–1)     0.78 ± 0.08
k–2 (min–1)     ∼4 × 10–11
Ki,1 (nM)     25 ± 6
Ki (nM)     b
t1/2 (min)     <105
a

The data correspond to mechanism B of slow-binding kinetics, except for the inhibition of HDACs 1 and 2 by compound 5, which follows mechanism A.

b

Ki was not determined because the value of k–2 obtained by data fitting approached zero.

c

The HDAC3 enzyme preparation contained the DAD of NCoR2.